Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Oct 25 - Oct 30
What the April 2026 Announcement Changes The FDA's April 15 announcement signals that injectable GHK-Cu will be removed from the Category 2 list, with formal implementation expected in July 2026 when the FDA's peptide advisory panel is scheduled to reconvene and finalize updated guidance
The published data shows meaningful but modest fat loss in clinical conditions, approximately 1 to 2 kg of additional fat loss over 12 weeks compared to placebo at 1 mg/day
Henke MO, John G, Germann M, Lindemann H, Rubin BK
Most products were tested from single vials
These properties make BPC-157 a particularly active subject of study in the fields of regenerative medicine and experimental gastroenterology
US$ 26.67
US$ 20.99
US$ 21.79
US$ 23.03
US$ 24.96
